201 related articles for article (PubMed ID: 19391277)
1. Rivastigmine patches: line extension. No therapeutic advantage and less convenient than capsules.
Prescrire Int; 2009 Feb; 18(99):19. PubMed ID: 19391277
[No Abstract] [Full Text] [Related]
2. [Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
Burian R
MMW Fortschr Med; 2010 Sep; 152(37):40-1. PubMed ID: 21192453
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Sadowsky CH; Farlow MR; Meng X; Olin JT
Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
[TBL] [Abstract][Full Text] [Related]
4. Cholinesterase inhibitors: tremor and exacerbation of Parkinson's disease.
Prescrire Int; 2007 Oct; 16(91):197-8. PubMed ID: 17926835
[TBL] [Abstract][Full Text] [Related]
5. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Winblad B; Grossberg G; Frölich L; Farlow M; Zechner S; Nagel J; Lane R
Neurology; 2007 Jul; 69(4 Suppl 1):S14-22. PubMed ID: 17646619
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
Yang LP; Keating GM
CNS Drugs; 2007; 21(11):957-65. PubMed ID: 17927299
[No Abstract] [Full Text] [Related]
7. A rivastigmine patch for dementia.
Med Lett Drugs Ther; 2008 Mar; 50(1282):21-2. PubMed ID: 18356801
[No Abstract] [Full Text] [Related]
8. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Blesa R; Ballard C; Orgogozo JM; Lane R; Thomas SK
Neurology; 2007 Jul; 69(4 Suppl 1):S23-8. PubMed ID: 17646620
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
Grossberg G; Sadowsky C; Fröstl H; Frölich L; Nagel J; Tekin S; Zechner S; Ros J; Orgogozo JM
Alzheimer Dis Assoc Disord; 2009; 23(2):158-64. PubMed ID: 19484917
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Lefèvre G; Sedek G; Jhee SS; Leibowitz MT; Huang HL; Enz A; Maton S; Ereshefsky L; Pommier F; Schmidli H; Appel-Dingemanse S
Clin Pharmacol Ther; 2008 Jan; 83(1):106-14. PubMed ID: 17522596
[TBL] [Abstract][Full Text] [Related]
11. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
[No Abstract] [Full Text] [Related]
12. Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
Prescrire Int; 2007 Apr; 16(88):66. PubMed ID: 17458048
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
Blesa González R; Boada Rovira M; Martínez Parra C; Gil-Saladié D; Almagro CA; Gobartt Vázquez AL;
Neurologia; 2011 Jun; 26(5):262-71. PubMed ID: 21227548
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic rationale for the rivastigmine patch.
Cummings J; Lefèvre G; Small G; Appel-Dingemanse S
Neurology; 2007 Jul; 69(4 Suppl 1):S10-3. PubMed ID: 17646618
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's drug proves ineffective for delirium.
Harv Ment Health Lett; 2011 Mar; 27(9):7. PubMed ID: 21476248
[No Abstract] [Full Text] [Related]
16. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
[TBL] [Abstract][Full Text] [Related]
17. Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.
Makris M; Koulouris S; Koti I; Aggelides X; Kalogeromitros D
Allergy; 2010 Jul; 65(7):925-6. PubMed ID: 19889118
[No Abstract] [Full Text] [Related]
18. Anti-Alzheimer drugs: life-threatening adverse effects.
Prescrire Int; 2007 Feb; 16(87):16. PubMed ID: 17326275
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Dhillon S
Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine exposure provided by a transdermal patch versus capsules.
Mercier F; Lefèvre G; Huang HL; Schmidli H; Amzal B; Appel-Dingemanse S
Curr Med Res Opin; 2007 Dec; 23(12):3199-204. PubMed ID: 18001519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
